Glabellar Lines
Pipeline by Development Stage
On Market (1)
Approved therapies currently available
Competitive Landscape
9 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 26 trials with date data
Clinical Trials (26)
Total enrollment: 6,773 patients across 26 trials
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines
Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)
A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines
A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines
Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
Dysport in the Treatment of Glabellar Lines in Chinese Subjects
A Study Of BOTOX For The Treatment Of Glabellar Lines
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
Phase 2 of HU-045 in Glabellar Lines
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL)
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
Prospective, Non-interventional Study Assessing Periorbital Rejuvenation Procedure
A Prospective, Non-Interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A
Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.